Literature DB >> 30938213

Immunogenicity of infliximab and adalimumab.

Giuseppe Murdaca1, Simone Negrini1, Monica Greco1, Chiara Schiavi1, Francesca Giusti1, Matteo Borro1, Francesco Puppo1.   

Abstract

Entities:  

Keywords:  Infliximab; adalimumab; biosimilars; hypersensitivity reactions; immunogenicity

Mesh：

Substances：

Year:  2019        PMID： 30938213     DOI： 10.1080/14740338.2019.1602117

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN： 1474-0338            Impact factor:   4.250


× No keyword cloud information.
  5 in total

1.  Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?

Authors:  Tasnim Abdalla; Michelle A Lowes; Nirmal Kaur; Robert G Micheletti; A Hillary Steinhart; Afsaneh Alavi
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 6.233

2.  What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?

Authors:  Puja Mehta; Jessica J Manson
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

Review 3.  Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Authors:  Zhuqian Wang; Jie Huang; Duoli Xie; Dongyi He; Aiping Lu; Chao Liang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

Review 4.  Development of Therapeutic Antibodies and Modulating the Characteristics of Therapeutic Antibodies to Maximize the Therapeutic Efficacy.

Authors:  Seung Hyun Kang; Chang-Han Lee
Journal:  Biotechnol Bioprocess Eng       Date:  2021-06-28       Impact factor: 2.836

5.  Methotrexate Enhances Apoptosis of Transmembrane TNF-Expressing Cells Treated With Anti-TNF Agents.

Authors:  Qiaolei Wang; Daisuke Oryoji; Hiroki Mitoma; Yasutaka Kimoto; Masamichi Koyanagi; Kana Yokoyama; Masahiro Ayano; Mitsuteru Akahoshi; Yojiro Arinobu; Hiroaki Niiro; Koichi Akashi; Takahiko Horiuchi
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.